The product is a topical corticosteroid indicated for the treatment of moderate to severe dermatosis of the scalp. As the first filer, Perrigo will be eligible for 180 days of generic marketing exclusivity once it launches the product.
Joseph Papa, Perrigo’s chairman and CEO, said: “This approval reflects our on-going efforts to make quality healthcare more affordable for our customers and drive value for our shareholders.”